Tiziana CEO buys 667,000 shares on Nasdaq

Tiziana Life Sciences Ltd reports that Chief Executive Officer Ivor Elrifi has increased his stake by purchasing 667,000 common shares on Nasdaq at $1.00 per share, bringing his total holding to 4,472,261 common shares.

Rhea-AI Filing Summary

Tiziana Life Sciences Ltd reports that Chief Executive Officer Ivor Elrifi has increased his stake by purchasing 667,000 common shares on Nasdaq at $1.00 per share, bringing his total holding to 4,472,261 common shares.

The company is a clinical-stage biotechnology firm focused on immunomodulation therapies, led by intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Fourteen patients with non-active secondary progressive multiple sclerosis have been dosed in an Expanded Access Program, all showing improvement or disease stability within six months, and a Phase 2a randomized, double-blind, placebo-controlled trial is ongoing.

Key Figures

Shares Purchased by CEO: 667,000 shares Purchase Price: $1.00 per share CEO Total Holdings: 4,472,261 shares +2 more

5 metrics

Shares Purchased by CEO 667,000 shares Common shares bought on Nasdaq by CEO Ivor Elrifi

Purchase Price $1.00 per share Price paid by CEO for newly purchased common shares

CEO Total Holdings 4,472,261 shares Total common shares held by CEO after the purchase

Patients Dosed in Expanded Access Program 14 patients Non-active secondary progressive multiple sclerosis patients dosed with intranasal foralumab

Outcome Assessment Period 6 months Period within which all 14 patients showed improvement or stability

Key Terms

Expanded Access (EA) Program, intranasal foralumab, anti-CD3 monoclonal antibody, non-active secondary progressive multiple sclerosis, +1 more

5 terms

Expanded Access (EA) Program medical

"dosed in an open-label intermediate sized Expanded Access (EA) Program"

intranasal foralumab medical

"lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody"

Intranasal foralumab is an experimental antibody medication given as a spray or drops into the nose that aims to change how the immune system behaves rather than attack a virus directly. Investors care because results from trials, safety findings, and regulatory decisions determine whether this approach can become a marketed therapy, affecting a company’s future sales, development costs and competitive position — similar to betting on a new product that could reshape a company’s revenue stream.

anti-CD3 monoclonal antibody medical

"Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate"

A lab-made antibody engineered to attach to CD3, a protein found on T cells, so it can change how those immune cells behave. Investors care because these drugs can act like a targeted brake on an overactive immune system—useful for autoimmune disease, transplant rejection or as part of cancer therapies—but they also carry clinical trial, safety and regulatory risks that determine commercial success.

non-active secondary progressive multiple sclerosis medical

"patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS)"

randomized, double-blind, placebo-controlled medical

"Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchase did Tiziana Life Sciences (TLSA) disclose?

Tiziana Life Sciences disclosed that CEO Ivor Elrifi purchased 667,000 common shares on Nasdaq at $1.00 per share. This transaction increases his total ownership to 4,472,261 common shares, reflecting a larger personal stake in the company.

At what price did the TLSA CEO buy additional shares and how many does he now own?

The CEO bought shares at $1.00 per share, acquiring 667,000 common shares. Following this purchase, his total holding in Tiziana Life Sciences amounts to 4,472,261 common shares, as reported in the August 4, 2026 announcement.

What is Tiziana Life Sciences (TLSA) developing with its lead candidate foralumab?

Tiziana Life Sciences is developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody for immunomodulation. The approach targets T regulatory cell stimulation and is being explored for neuroinflammatory and neurodegenerative diseases, including non-active secondary progressive multiple sclerosis.

How many patients have received intranasal foralumab in Tiziana Life Sciences’ Expanded Access Program?

Tiziana Life Sciences reports that 14 patients with non-active secondary progressive multiple sclerosis have been dosed with intranasal foralumab in an open-label Expanded Access Program. All showed either disease improvement or stability within 6 months of treatment.

What clinical trial is intranasal foralumab in according to the TLSA update?

Intranasal foralumab is currently in a Phase 2a randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in non-active secondary progressive multiple sclerosis. The trial is identified as NCT06292923 and further evaluates safety and clinical response.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 07:00 AM Accepted by SEC EDGAR 08/04/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

August 2026

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On August 4, 2026, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, that its Chief Executive Officer, Ivor Elrifi has increased his holdings with the purchase of 667,000 of the Company’s common shares on NASDAQ at $1.00 per share, bringing his total holding to 4,472,261 common shares.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: August 4, 2026	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated August 4, 2026

3

Exhibit 99.1

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

BOSTON, MA, August 4, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Chief Executive Officer, Ivor Elrifi has increased his holdings with the purchase of 667,000 of the Company’s common shares on NASDAQ at $1.00 per share, bringing his total holding to 4,472,261 common shares.

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd

Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED AUGUST 4, 2026 8.3 KB